Targets and investigative treatments for primary biliary cholangitis

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Orphan Drugs

• Publication date

  2016-09-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/21678707.2016.1227240
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof‐of‐concept study

  2016cited by this paper
• Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score

  2016cited by this paper
• Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes

  2016cited by this paper
• Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.

  2015cited by this paper
• Engineered FGF19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice

  2015cited by this paper
• Role of Novel Retroviruses in Chronic Liver Disease: Assessing the Link of Human Betaretrovirus with Primary Biliary Cirrhosis

  2015cited by this paper
• Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis

  2015cited by this paper
• Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis

  2015cited by this paper
• Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

  2015cited by this paper
• A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia

  2015cited by this paper
• International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

  2015cited by this paper
• Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis

  2015cited by this paper
• The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis

  2014cited by this paper
• Allogeneic Bone Marrow Mesenchymal Stem Cell Transplantation in Patients with UDCA-Resistant Primary Biliary Cirrhosis

  2014cited by this paper
• Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.

  2014cited by this paper
• Pruritus in cholestasis: Facts and fiction

  2014cited by this paper
• Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease

  2014cited by this paper
• The bile acid TGR5 membrane receptor: from basic research to clinical application.

  2014cited by this paper
• Peroxisome proliferator‐activated receptor α activates human multidrug resistance transporter 3/ATP‐binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion

  2014cited by this paper
• Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

  2014cited by this paper
• B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid

  2013cited by this paper
• Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come

  2013cited by this paper
• Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis

  2013cited by this paper
• A pilot study of umbilical cord‐derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis

  2013cited by this paper
• Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.

  2012cited by this paper
• Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature

  2012influential reference
• Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy

  2012cited by this paper
• Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist

  2012cited by this paper
• Primary biliary cirrhosis and bile acids.

  2012cited by this paper
• Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

  2012cited by this paper
• Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis.

  2012cited by this paper
• S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility.

  2012cited by this paper
• Progress in the genetics of primary biliary cirrhosis.

  2011cited by this paper
• Dual farnesoid X receptor/TGR5 agonist INT‐767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO  3− output

  2011cited by this paper
• Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.

  2011cited by this paper
• No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!

  2011cited by this paper
• Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

  2011cited by this paper
• Deciphering the nuclear bile acid receptor FXR paradigm

  2010cited by this paper
• Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study

  2010cited by this paper
• American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis

  2010cited by this paper
• Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis

  2010cited by this paper
• Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid

  2009cited by this paper
• EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

  2009cited by this paper
• Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.

  2009cited by this paper
• The enterohepatic circulation of bile acids in mammals: form and functions.

  2009cited by this paper
• B‐cell depletion with anti‐CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor‐β receptor II dominant negative mice

  2009cited by this paper
• Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis

  2008cited by this paper
• Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.

  2008cited by this paper
• Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol

  2008cited by this paper
• Ursodeoxycholic Acid for Patients With Primary Biliary Cirrhosis: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials Using Bayesian Approach as Sensitivity Analyses

  2007cited by this paper
• AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Antimitochondrial Antibodies in Acute Liver Failure: Implications for Primary Biliary Cirrhosis

  2007cited by this paper
• Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger.

  2006cited by this paper
• Bicarbonate‐rich choleresis induced by secretin in normal rat is taurocholate‐dependent and involves AE2 anion exchanger

  2006cited by this paper
• Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.

  2006cited by this paper
• Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview‐based study of 1032 patients

  2005cited by this paper
• Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature

  2005cited by this paper
• Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial

  2005cited by this paper
• Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

  2005cited by this paper
• Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis.

  2005cited by this paper
• Proof of Principal Studies to Assess the Role of the Human Betaretrovirus in Patients with Primary Biliary Cirrhosis

  2004cited by this paper
• Pilot Studies of Single and Combination Antiretroviral Therapy in Patients with Primary Biliary Cirrhosis

  2004cited by this paper
• Pharmacokinetics and pharmacodynamic action of budesonide in early‐ and late‐stage primary biliary cirrhosis

  2003cited by this paper
• When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?

  2003cited by this paper
• Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis.

  2003cited by this paper
• Bezafibrate treatment: a new medical approach for PBC patients?

  2003cited by this paper
• Fenofibrate treatment in patients with primary biliary cirrhosis

  2002cited by this paper
• Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years.

  2002influential reference
• 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

  2002cited by this paper
• Risk factors for primary biliary cirrhosis in a cohort of patients from the United States

  2001cited by this paper
• Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

  2000cited by this paper
• Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.

  2000cited by this paper
• Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial

  2000cited by this paper
• Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid

  2000cited by this paper
• Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

  2000cited by this paper
• Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

  1999cited by this paper
• Bile acids: natural ligands for an orphan nuclear receptor.

  1999cited by this paper
• Ten‐year survival in ursodeoxycholic acid–treated patients with primary biliary cirrhosis

  1999cited by this paper
• Identification of a nuclear receptor for bile acids.

  1999cited by this paper
• Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.

  1999cited by this paper
• Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.

  1999cited by this paper
• Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis

  1999cited by this paper
• Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.

  1999cited by this paper
• Primary biliary cirrhosis

  1998cited by this paper
• Characterization of antimitochondrial antibodies in healthy adults

  1998influential reference
• Fatigue in primary biliary cirrhosis

  1998cited by this paper
• Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.

  1997cited by this paper
• Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis.

  1997cited by this paper
• Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.

  1996cited by this paper
• Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions*

  1996cited by this paper
• Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis.

  1996cited by this paper
• Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4*

  1996cited by this paper
• The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study

  1995cited by this paper
• Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

  1994cited by this paper
• Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study.

  1994cited by this paper
• Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.

  1994cited by this paper
• The canadian multicenter double‐blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis

  1994cited by this paper
• A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis

  1993cited by this paper
• KOMBINIERTE URSODEOXYCHOLSAURE PLUS COLCHIZIN-BEHANDLUNG BEI PRIMAR BILIARER ZIRRHOSE : ERGEBNISSE EINER PLACEBO-KONTROLLIERTEN DOPPELBLINDSTUTIE

  1992cited by this paper
• [Combined ursodeoxycholic acid plus colchicine--treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study].

  1992cited by this paper
• A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.

  1991cited by this paper

• No citing papers are available for this paper.